



# Webinar for Stakeholder Engagement on the New Draft Guideline on General Considerations for Patient Preference Studies (ICH E22)

6 February 2026, 13:30 – 17:00 (CET)

The new draft ICH E22 guideline addresses general considerations for patient preference studies (PPS) to inform drug development and regulatory submissions. It aims to harmonise patient preference studies using a globally agreed framework.

This webinar presents the draft E22 guideline, seeking to encourage stakeholder feedback to incorporate their insights and experiences into the development of ICH E22.

The objectives of the webinar are to:

- Describe the draft E22 guideline and facilitate timely stakeholder engagement;
- Encourage stakeholder feedback during the public consultation;
- Support the development of training materials.

**The meeting is open to the public via a broadcast link—no pre-registration is required:**  
<https://vimeo.com/event/2906642>

# Programme

## 13:15 Joining and technical checks

---

## 13:30 Welcome and opening speeches

---

- **Welcome and objectives of the meeting (F. Pignatti; EC, Europe)**
- **Keynote: Setting the stage for ICH E22 (T. Mullin; FDA, United States)**
- **ICH E22 – General considerations for PPS (video)**
- **ICH public consultation process (S. Almuhaidib; SFDA, Saudi Arabia)**

## 14:10 Session 1: ICH E22 - Overview and Key Concepts

---

In this session, Expert Working Group members will present key aspects of the ICH E22 guideline, focusing on use cases and general methodological considerations of patient preference studies, and will introduce proposed training materials, including FAQs and illustrative examples.

- **Purpose, scope, and key concepts (S. Tezuka; MHLW/PMDA, Japan)**
- **Common uses of PPS (B. Hauber; PhRMA)**
- **General methodological considerations (L.L. Johnson; FDA, United States)**
- **Patient input in the development of PPS (S. Dickinson; EFPIA)**
- **Frequently asked questions and examples (B. Levitan; PhRMA)**

## 15:30 Break

---

## 16:00 Session 2: ICH E22 – Providing significant feedback

---

Moderated by: R. Bent, FDA United States

- **Panel: J. Harris (National Psoriasis Foundation); F. Houyez (EURORDIS); N. Sakurai (Cancer Solution co, LTD); A. Valentine (Sick Cells)**

In this session, members of the ICH E22 Expert Working Group will hear from invited patient representatives across different regions about their experiences with patient preference studies and gather initial feedback on the guideline. The goal is to foster meaningful engagement by encouraging comments related to the scope of the ICH E22 guideline, describing stakeholder perspectives, and

providing examples of substantive feedback during the public consultation process. Rather than a traditional Q&A format, this interactive discussion is designed to facilitate constructive feedback that will inform the ongoing development of the guideline.

### **16:50 Closing remarks**

---

- **Wrap up (F. Pignatti; EC, Europe)**

**17:00            Meeting ends**

---